Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

TORONTO -- Biomarkers pointing to increased risk for Alzheimer's disease were markedly reduced with the investigational cholesteryl ester transfer protein (CETP) inhibitor obicetrapib relative to ...

Compared with eligible people who were not participating in the U.S. Supplemental Nutritional Assistance Program, SNAP ...

Scientists found genetic elements linked to hibernation in the human genome. Tapping into them could produce a new wave of ...

A Scots chemist believes drugs to treat Alzheimer's disease will be available within five years. Professor David MacMillan, ...

A Wellington man is being held on $2 million bond after authorities say he exploited his elderly mother, siphoning off more ...

A computer program predicts with more than 75% accuracy who will develop dementia in the near future.

The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Daily doses of obicetrapib over 52 weeks led to significant reductions in plasma p-tau217 and other Alzheimer’s disease ...

Dr. Kurt Hong, a nutrition researcher and professor of medicine and aging, told Business Insider he sees age as just a number ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...